Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Other Non-Current Assets: 2019-2024

  • Burning Rock Biotech's Other Non-Current Assets rose 51.25% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year increase of 51.25%. This contributed to the annual value of $1.1 million for FY2024, which is 51.25% up from last year.
  • According to the latest figures from Q4 2024, Burning Rock Biotech's Other Non-Current Assets is $1.1 million, which was up 51.25% from $718,000 recorded in Q4 2023.
  • Burning Rock Biotech's Other Non-Current Assets' 5-year high stood at $7.1 million during Q4 2021, with a 5-year trough of $718,000 in Q4 2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.1 million (2022), whereas its average is $2.0 million.
  • Per our database at Business Quant, Burning Rock Biotech's Other Non-Current Assets skyrocketed by 127.00% in 2020 and then tumbled by 76.30% in 2023.
  • Burning Rock Biotech's Other Non-Current Assets (Quarterly) stood at $3.5 million in 2020, then spiked by 100.77% to $7.1 million in 2021, then crashed by 57.24% to $3.0 million in 2022, then slumped by 76.30% to $718,000 in 2023, then skyrocketed by 51.25% to $1.1 million in 2024.
  • Its Other Non-Current Assets stands at $1.1 million for Q4 2024, versus $718,000 for Q4 2023 and $3.0 million for Q4 2022.